In particular, combination therapy of anti-LAG-3 (BMS-986016) plus anti-PD-1 (nivolumab) has shown impressive clinical efficacy in melanoma patients who are resistant to anti-PD-1/PD-L1 therapy [19, 20]. Here, CD274 is linked to melanoma.